Dubai, United Arab Emirates - The pharmaceutical sector in the MENA has witnessed tremendous growth over the last few years and is projected to reach around $60 billion by 2025. With governments in the region focusing more and more on the wellbeing of a growing population and enhancing healthcare services, timely and safe delivery of medical supplies and pharmaceuticals, especially temperature controlled products has become a vital for the sector.
Middle East Pharma Cold Chain Congress happening between 19-21 March at Millennium Airport Hotel in Dubai is an important platform for the pharmaceutical industry in MENA discussing ongoing and future challenges and solutions in the industry.
According to studies, the pharma sector growth is largely fueled by high population growth, increased life expectancy coupled with the prevalence of lifestyle-related diseases such as diabetes, and aspiration for excellent healthcare services among countries in the region. The UAE is leading the growth with over $1.2 billion funneled into the healthcare system in the 2019 budget, and topped up with more support with substantial funds allotted in the $540 million innovation fund by His Highness Sheikh Mohammed bin Rashid Al Maktoum Fund.
With the recent approval of Dubai Silk Road Strategy and existing outstanding logistics infrastructure, the UAE is fast turning into a source market, which is manufacturing and exporting pharmaceuticals to high-demand markets such as Africa and Asia. Accelerated drug-registration system, investments in R&D, innovation, and technological advancement, has led to a rise in the number of international pharmaceutical companies from 30 in 2013 to 47 in 2016, and is expected to reach 75 in 2020. Moreover, around 95% of the global pharmaceutical companies have a base in the UAE, which gives them logistics access to 43 countries worldwide.
The Congress will focus on challenges faced by pharmaceutical companies in the Middle East and North Africa (MENA) with the globalisation of the pharmaceutical supply chain requiring them to maintain ever-changing regulations and compliance for temperature-sensitive products. It will also discuss Good Distribution Practices and varying regulations across different countries. It will delve into strategies including regulatory compliance, integrating cold chain management, selecting the appropriate partners, maintaining supply chain integrity, achieving real-time traceability and more.
The Middle East Pharma Cold Chain Congress is co-organised by Saudi Pharmaceutical Society and Maarefah Management and supported by leading pharmaceutical companies including Global Pharma, LisaLine, Zakłady Farmaceutyczne UNIA Spółdzielnia Pracy, Polish Investment and Trade Agency, and Technical Supplies & Services Co.L.L.C.
-Ends-
About Maarefah Management:
Maarefah Management is a world-class events, training and association management company that works closely with government institutions, industry bodies, and professional associations to help individual’s career development in order to grow and sustain successful businesses. Through four main divisions, Maarefah offers comprehensive professional services ranging from events management, leadership development training, market research and association administration across a number of industries. The company’s conferences and specialized training courses are developed by well experienced technical committees who create up-to-date scientific and technical programs tackling current and critical industry issues. Visit: http://www.maarefah-management.com
For more information:
Paula Popova
Business Development Manager
Maarefah Management DMCC
M: +971 58 895 7245
E: paula.p@maarefah-management.org
For Media Queries:
Nafeesa Mohammed
PR Manager
International Cold Chain Management Congress
Mail: nafeesampallikunhi@gmail.com
Mob: +971508274288
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
